The Swiss vaccine developer GlycoVaxyn has ginned $22 million for its Series B round. Edmond de Rothschild Investment Partners led the round with Index Ventures and Sofinnova Partners joining in. GlycoVaxyn is a platform company, using new technology to engineer a new type of conjugate vaccine, glycoconjugates, that can be used to combat bacterial infections. The new money will help push its lead program for intestinal infections into the clinic in 12 months while giving its team more time to hit its milestones on vaccines for Staphylococcus aureus, Group B meningococcal and Group A Streptococcus. Article